Want to join the conversation?
Biopharmaceutical company $AMGN said that in Phase 2 confirmatory multicenter single-arm trial (BLAST) for adult patients having B-cell precursor acute lymphoblastic leukemia with minimal residual disease (MRD), i.e. cancer cells from bone marrow, who received BLINCYTO monotherapy showed clinically relapse-free survival (RFS).
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!